Accuray cyberknife® robotic radiotherapy platform is superior to conventional linear accelerators in reducing incidence of bladder side effects in prostate cancer patients

Sunnyvale, calif., sept. 14, 2021 /prnewswire/ -- accuray incorporated (nasdaq: aray) announced today that data from the pace – prostate advances in comparative evidence – trial indicate the company's cyberknife ® robotic radiotherapy platform is superior to conventional linear accelerators in reducing the incidence of late grade two or higher bladder toxicity associated with prostate cancer stereotactic body radiation therapy (sbrt) treatments.
ARAY Ratings Summary
ARAY Quant Ranking